Latest tumor Stories
Caris Molecular Intelligence Tumor Profiling Data Presented at ASCO Highlights Drug Efflux Pump Expression and PIK3CA Pathway Aberrations from 50,000 Tumors and 20,000 Tumors Respectively
IRVING, Texas, May 27, 2015 /PRNewswire/ -- Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced it has appointed
Virginia Cancer Specialists Joins Caris Centers of Excellence for Precision Medicine Network to Help Develop Guidelines and Standards of Care for Tumor Profiling IRVING, Texas, May
Aldoxorubicin Has Now Shown Two Complete Responses, In Addition to Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, May 21, 2015 /PRNewswire/
Unusually broad range of tumors treated, other benefits seen in first year-plus of operation SAN DIEGO, May 20, 2015 /PRNewswire/ -- The nation's first and only proton therapy center
MADRID, May 14, 2015 /PRNewswire/ -- - Compelling clinical activity of PM1183 in second line, achieving 67% response rate and a progression-free
Research Demonstrates Clinical Utility of Caris Molecular Intelligence and Advances Molecular Understanding of Cancer to Enable the Delivery of Precision Medicine IRVING, Texas, May 14, 2015
Abstracts: 5034, TPS5082, 5063, TPS1104, 3558, 3560, 6015, TPS5080 WHIPPANY, N.J., May 13, 2015 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
THOUSAND OAKS, Calif., May 13, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data at the 51(st) Annual Meeting of the American Society of Clinical Oncology (ASCO) will showcase the
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.